Dr. Efstathiou on safety of niraparib/abiraterone in mCRPC
The toxicity profile was consistent with the first interim analysis of the phase 3 MAGNITUDE study with no new safety signals observed.
Eleni Efstathiou, MD, PhD, medical oncologist, and section chief of Genitourinary Medical Oncology at Houston Methodist Cancer Center in Texas, discusses safety data from the second interim analysis of the phase 3 MAGNITUDE study (NCT03748641), which she presented at the 2023 Genitourinary Cancers Symposium.
The study compared niraparib (Zejula) plus abiraterone acetate (Zytiga) and prednisone versus abiraterone and prednisone alone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
The toxicity profile was consistent with the first interim analysis, and no new safety signals were observed. Adverse effects (AEs) were generally more common among patients treated with niraparib. The most frequent AEs in the niraparib and placebo groups were anemia (50.0% vs 22.7%), hypertension (33.0% vs 22.3%), and constipation (33.0% vs 15.6%).
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
